Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

被引:33
|
作者
Freedman, Gary M. [1 ]
Anderson, Penny R. [2 ]
Bleicher, Richard J. [4 ]
Litwin, Samuel [3 ]
Li, Tianyu [3 ]
Swaby, Ramona F. [5 ]
Ma, Chang-Ming Charlie [2 ]
Li, Jinsheng [2 ]
Sigurdson, Elin R. [4 ]
Watkins-Bruner, Deborah [6 ]
Morrow, Monica [7 ]
Goldstein, Lori J. [5 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[6] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 04期
关键词
Breast boost; Breast cancer; Hypofractionation; IMRT; Radiation therapy; CONSERVING SURGICAL-PROCEDURES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADIOTHERAPY; WOMEN; IRRADIATION; SURGERY; FORM; RT;
D O I
10.1016/j.ijrobp.2012.01.091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged >= 18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost. (C) 2012 Elsevier Inc.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [41] A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer
    Oermann, Eric K.
    Slack, Rebecca S.
    Hanscom, Heather N.
    Lei, Sue
    Suy, Simeng
    Park, Hyeon U.
    Kim, Joy S.
    Sherer, Benjamin A.
    Collins, Brian T.
    Satinsky, Andrew N.
    Harter, K. William
    Batipps, Gerald P.
    Constantinople, Nicholas L.
    Dejter, Stephen W.
    Maxted, William C.
    Regan, James B.
    Pahira, John J.
    McGeagh, Kevin G.
    Jha, Reena C.
    Dawson, Nancy A.
    Dritschilo, Anatoly
    Lynch, John H.
    Collins, Sean P.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2010, 9 (05) : 453 - 462
  • [42] PHASE II TRIAL OF HYPERFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY AND CONCURRENT WEEKLY CISPLATIN FOR STAGE III AND IVa HEAD-AND-NECK CANCER
    Maguire, Patrick D.
    Papagikos, Michael
    Hamann, Sue
    Neal, Charles
    Meyerson, Martin
    Hayes, Neil
    Ungaro, Peter
    Kotz, Kenneth
    Couch, Marion
    Pollock, Hoke
    Tepper, Joel
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1081 - 1088
  • [43] Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer
    Freedman, Gary M.
    Meropol, Neal J.
    Sigurdson, Elin R.
    Hoffman, John
    Callahan, Elaine
    Price, Robert
    Cheng, Jonathan
    Cohen, Steve
    Lewis, Nancy
    Watkins-Bruner, Deborah
    Rogatko, Andre
    Konski, Andre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (05): : 1389 - 1393
  • [44] A Case of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer in a Patient With Fabry Disease
    Honda, Motoki
    Ishikawa, Yojiro
    Ito, Kengo
    Teramura, Satoshi
    Yasuhiro, Seki
    Yamada, Takayuki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [45] Correlation between toxicity and dosimetric parameters for adjuvant intensity modulated radiation therapy of breast cancer: a prospective study
    Pasquier, David
    Bataille, Benoit
    Le Tinier, Florence
    Bennadji, Raoudha
    Langin, Helene
    Escande, Alexandre
    Tresch, Emmanuelle
    Darloy, Franck
    Carlier, Damien
    Crop, Frederik
    Lartigau, Eric
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [46] Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial
    Beaudry, M. M.
    Carignan, D.
    Foster, W.
    Lavallee, M. C.
    Aubin, S.
    Lacroix, F.
    Poulin, E.
    Lachance, B.
    Despres, P.
    Beaulieu, L.
    Vigneault, E.
    Martin, A. G.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 40
  • [47] Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma Early results of a phase II study
    Yu, Wei-Wei
    Zhu, Zheng-Fei
    Fu, Xiao-Long
    Zhao, Kuai-Le
    Mao, Jing-Fang
    Wu, Kai-Liang
    Yang, Huan-Jun
    Fan, Min
    Zhao, Sen
    Welsh, James
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (11) : 979 - 986
  • [48] Five-year Follow-up of Health-related Quality of Life after Intensity-modulated Radiation Therapy for Prostate Cancer
    Namiki, Shunichi
    Ishidoya, Shigeto
    Ito, Akihiro
    Tochigi, Tatsuo
    Numata, Isao
    Narazaki, Kakutaro
    Yamada, Shogo
    Takai, Yoshihiro
    Arai, Yoichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (11) : 732 - 738
  • [49] Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
    Noha Jastaniyah
    Albert Murtha
    Nadeem Pervez
    Duc Le
    Wilson Roa
    Samir Patel
    Marc Mackenzie
    Dorcas Fulton
    Colin Field
    Sunita Ghosh
    Gino Fallone
    Bassam Abdulkarim
    Radiation Oncology, 8
  • [50] Radiation dose to the low axilla in patients treated for early -stage breast cancer by locoregional intensity -modulated radiotherapy (IMRT)
    Abbassi, L. M.
    Arsene-Henry, A.
    Amessis, M.
    Kirova, Y. M.
    CANCER RADIOTHERAPIE, 2022, 26 (03): : 445 - 449